长城:用于药物组合试验的通用剂量优化设计,最大限度地提高生存效益
Yan Han1, Yingjie Qiu2, Yi Zhao1
1Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Pharmaceutical statistics
|November 12, 2025
概括
长城的设计优化了临床试验中的药物组合,通过平衡早期的毒性和疗效来最大限度地提高长期存活率,解决最初反应后复发等问题.
科学领域:
- 临床试验 临床试验
- 药理学 药理学是指药理学的学科.
- 生物统计学 生物统计学
背景情况:
- 许多I-II期药物组合试验假设早期最佳剂量选择可确保长期生存.
- 这种假设经常与临床研究中初始反应后的高复发率相矛盾.
研究的目的:
- 介绍长城设计,用于药物组合试验的新型剂量优化策略.
- 通过优化剂量组合来解决最大限度地提高长期生存益处的挑战.
主要方法:
- 长城的设计使用了"分裂与征服"算法,用于毒性的部分顺序.
- 它使用早期结果来消除次优剂量组合和剂量随机化,以创建候选集.
- 候选组中的患者被监测生存结果,以选择最终的最佳剂量组合.
主要成果:
- 模拟研究表明,在各种临床场景中,长城设计具有有利的操作特征.
- 该设计有效地平衡了毒性和早期疗效,以确定最大限度地提高生存效益的剂量组合.
结论:
- 长城的设计为药物组合试验提供了一种实用和模块化的方法,优先考虑长期生存.
- 它的实用性尤其重要,当延长患者随访以评估生存是可行的.
相关概念视频
Dosage Regimens: Designs and Approaches
248
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
248
Bioavailability Study Design: Single Versus Multiple Dose Studies
189
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
189
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
211
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
211
Dosage Regimen: Individualization
160
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
160
Dosage Regimens: Partial Pharmacokinetic Parameters
141
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
141


